NASDAQ:AVTE

Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

Aerovate Therapeutics logo
$15.34 -0.81 (-4.99%)
As of 11/16/2026

About Aerovate Therapeutics Stock (NASDAQ:AVTE)

Advanced

Key Stats

Today's Range
$14.95
▼
$16.08
50-Day Range
$13.41
▼
$19.45
52-Week Range
$89.95
▼
$99.05
Volume
1.13 million shs
Average Volume
53,591 shs
Market Capitalization
$444.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aerovate Therapeutics was a clinical-stage biopharmaceutical company focused on developing treatments for pulmonary arterial hypertension, a rare and serious lung and heart condition. Its lead candidate, AV-101, was an inhaled formulation of imatinib designed to deliver the drug to the lungs.

The company evaluated AV-101 in clinical studies, but discontinued its Phase 2b program after the trial did not meet its goals. Aerovate later combined with Jade Biosciences, a biotechnology company focused on autoimmune diseases.

AI Generated. May Contain Errors.

Receive AVTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AVTE Stock News Headlines

Aerovate Therapeutics (NASDAQ:AVTE) Stock Jumps 3.2% - Still a Buy?
Unbelievable…Congress is About to Do What?
Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.tc pixel
See More Headlines

AVTE Stock Analysis - Frequently Asked Questions

Aerovate Therapeutics' stock was trading at $15.43 at the beginning of 2026. Since then, AVTE shares have decreased by 0.6% and is now trading at $15.3350.

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) issued its quarterly earnings data on Friday, April, 25th. The company reported ($3.15) EPS for the quarter, beating the consensus estimate of ($10.50) by $7.35.

Shares of Aerovate Therapeutics reverse split on the morning of Tuesday, April 29th 2025.A 1-35 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Aerovate Therapeutics (AVTE) raised $122 million in an IPO on Tuesday, June 29th 2021. The company issued 8,682,142 shares at a price of $13.00-$15.00 per share.

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AVTE
CIK
1798749
Fax
N/A
Employees
20
Year Founded
2018

Profitability

EPS (Trailing Twelve Months)
($1.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$75.52 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-90.19%
Return on Assets
-77.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.78
Quick Ratio
8.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.96 per share
Price / Book
3.87

Miscellaneous

Outstanding Shares
28,985,000
Free Float
21,685,000
Market Cap
$444.48 million
Optionable
Optionable
Beta
0.95

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:AVTE) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners